OSUR Earnings Date: Nov 9, 2026 (Estimated) — OraSure Technologies, Inc.
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is OSUR's next earnings date?
OraSure Technologies, Inc. (OSUR) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.18 on revenue of $31.0M.
How did OSUR do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), OraSure Technologies, Inc. posted EPS of -$0.20 versus the -$0.27 estimate, a beat of 11.1%. Revenue was $30.6M against a $29.1M estimate. The stock's 1-day post-earnings move was -3.6%.
How much does OSUR stock move after earnings?
OSUR beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.6% (up or down) in the day after earnings.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.27 | -0.20 | -11.11% | $30.6M | ✅ Beat | -3.61% | -9.64% | -13.73% |
| 2026-05-06 | Q1 2026 | -0.17 | -0.24 | -41.18% | $27.9M | ❌ Miss | +4.33% | +1.33% | +34.67% |
| 2026-02-25 | Q4 2025 | -0.18 | -0.19 | -5.56% | $26.8M | ❌ Miss | +10.00% | +7.50% | +9.64% |
| 2025-11-05 | Q3 2025 | -0.17 | -0.13 | +23.53% | $27.1M | ✅ Beat | -6.61% | -3.89% | -3.11% |
| 2025-08-05 | Q2 2025 | -0.17 | -0.19 | -11.76% | $31.2M | ❌ Miss | -8.49% | -10.26% | +0.96% |
| 2025-02-25 | Q4 2024 | -0.01 | -0.06 | -500.00% | $37.4M | ❌ Miss | -23.50% | -15.75% | -15.25% |
| 2024-11-06 | Q3 2024 | -0.08 | -0.01 | +87.50% | $39.9M | ✅ Beat | -3.64% | -7.95% | -11.14% |
| 2024-08-06 | Q2 2024 | -0.03 | 0.07 | +333.33% | $54.3M | ✅ Beat | +0.46% | -3.70% | +3.47% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $30.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product And Services | 97.0% | $29.7M | -0.4% | $91.2M | $29.0M | $29.8M | $25.3M |
| Other Revenues | 3.0% | $915K | -34.4% | $599K | $934K | $1.4M | $1.7M |
By region
Q2 FY26 · $30.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 66.0% | $20.2M | +1.9% | $68.6M | $20.3M | $19.9M | $19.7M |
| Africa | 22.1% | $6.8M | -15.5% | — | $7.2M | $8.0M | $4.9M |
| Other Foreign Countries | 6.1% | $1.9M | +50.5% | — | $770K | $1.2M | $1.2M |
| Europe | 5.7% | $1.7M | -17.7% | $4.7M | $1.6M | $2.1M | $1.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.